Article

Optos receives 510K clearance for ultra-widefield angiography system

New Orleans-Optos received 510K marketing clearance from the FDA for the Optos P200A Ultra-Widefield Scanning Laser System.

The image generated by the device, Optos Angiomap, provides diagnostic information across approximately 200 degrees of internal viewing angle of the retina. This advanced angiography test enables the retinal specialist and comprehensive ophthalmologist to view the extent of peripheral disease progression in a unique way; customize therapy to each patient's diagnosis; view retinal landmarks that facilitate therapy; and provide a unique ability to document and monitor post-treatment efficacy in the peripheral retina.

The Optos Panoramic200A contains three lasers that provide red, green, and blue wavelengths. The instrument is capable of producing the current red/green color and monochromatic Optomap image, but with the addition of a blue laser and enhanced software, the instrument is capable of angiography as well. The angiographic mode will allow capturing a sequence of ultra-wide field retinal images as fluorescein dye flows through the retinal vessels.

"With the addition of the Optos Angiomap and P200A, Optos is expanding its product line into high-resolution angiography with the unique ability to perform high-resolution documentation of retinal disease in the far periphery as well as the central pole. This may prove to be very important in diabetic diagnosis and treatment, as well as in managing other diseases where peripheral retinal condition is, or proves to be, important," said Stephane Sallmard, chief executive officer, Optos.

This system will be available for general use in the coming months.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.